Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0KJHHN
ADC Name
IMGN-779
Synonyms
IMGN 779; IMGN-779; IMGN7 79; IMGN779
   Click to Show/Hide
Organization
ImmunoGen, Inc.
Drug Status
Phase 1 (Terminated)
Indication
In total 1 Indication(s)
Acute myeloid leukaemia
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
3
Structure
Antibody Name
Z4681A
  Antibody Info 
Antigen Name
Myeloid cell surface antigen CD33 (CD33)
  Antigen Info 
Payload Name
DGN462
  Payload Info 
Therapeutic Target
Human Deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
Sulfo-SPDB
  Linker Info 
Conjugate Type
Random Lysines
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 100
%
EoL-1 cells
Chronic eosinophilic leukemia
Tumor Growth Inhibition value (TGI) 
≈ 100
%
MV4-11 cells
Childhood acute monocytic leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 15) Positive CD33 expression (CD33+++/++)
Method Description
EOL-1 tumor-bearing mice received a single intravenous bolus administration of vehicle, IMGN779, or Ab-DGN462, with each conjugate molecule dosed at approximately 1.5 mg/kg ADC by antibody concentration (i.e., 10 or 30 ug/kg linked IGN).
In Vivo Model EOL-1 CDX model
In Vitro Model Chronic eosinophilic leukemia EoL-1 cells CVCL_0258
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 30) Positive CD33 expression (CD33+++/++)
Method Description
IMGN779 (0.5 mg/kg, a single dose) induces efficient tumor cell killing in cell line-derived models of MV4-11 cells with CD33 expression with high expression.
In Vivo Model MV4-11 CDX model
In Vitro Model Childhood acute monocytic leukemia MV4-11 cells CVCL_0064
References
Ref 1 IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML. Mol Cancer Ther. 2018 Jun;17(6):1271-1279. doi: 10.1158/1535-7163.MCT-17-1077. Epub 2018 Mar 27.